Skip to content

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)

We are honoured to announce that our esteemed advisor, Prof. Dr. Petter Brodin, has launched the “imPROving Quality of LIFe In the Long COVID Patient (PROLIFIC)” study in partnership with Karolinska University Hospital and Pfizer.

This groundbreaking study aims to investigate the efficacy of orally administered nirmatrelvir/ritonavir in improving the quality of life for non-hospitalized adult participants suffering from post-acute COVID-19 syndrome (PACS). Currently, there is no curative treatment for PACS, and the focus is on symptom management and personalized rehabilitation.

Petter Brodin’s interventional, randomized, and placebo-controlled clinical intervention trial will evaluate the potential benefits of nirmatrelvir/ritonavir (Paxlovid®) compared to placebo/ritonavir. The study will enrol 400 patients with severe PACS, identified from a database of 988 patients who have received comprehensive clinical and laboratory examinations at the Karolinska University Hospital Post-COVID clinics since May 2020.

In addition to assessing the impact on patients’ quality of life, the study includes deep exploratory systems-level analyses of the immune system in PACS patients, investigating the changes induced by nirmatrelvir/ritonavir treatment. This research holds significant promise in addressing the unmet medical needs of non-hospitalized patients with post-COVID, shedding light on potential long-term solutions.

We extend our deepest gratitude to Petter Brodin for his invaluable contribution to the field of long COVID research. His dedication and expertise in the study’s design and implementation will undoubtedly advance our understanding and provide new hope for individuals suffering from this challenging condition.

Stay tuned for updates as we eagerly follow the progress of the PROLIFIC study and its potential impact on improving the lives of post-COVID patients.

Read more about it below:

https://clinicaltrials.gov/ct2/show/NCT05823896 

#PROLIFICstudy #LongCOVID #ResearchInnovation #MedicalBreakthrough #QualityofLife #ProudAdvisor

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Recent News

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Recent News

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

Recent News

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News

01 /04

Scailyte is fundraising!

Scailyte is kicking off its new fundraising campaign! We are seeking like-minded investors who share...

Read more

Scailyte and Visterra Partner to Advance Autoimmune Disease Research

Scailyte AG, an AI-driven biomarker discovery company, and Visterra, Inc., a clinical-stage biopharm...

Read more

Recent News

02 /04

Precision Medicine and The Future of Genomics Summit 2024

Scailyte at the Global Stage of Precision Medicine – PMFG 2024! We are proud to share that our CEO...

Read more

Exploring Type 2 T Cell Immunity in Cancer—A Single-Cell Revolution

In this issue of ScaiDigest, we highlight two groundbreaking studies that expand the boundaries of i...

Read more

Recent News

03 /04

Pitch Nic 2024 at Novartis Campus

We’re thrilled to announce that our CEO, Peter Nestorov will join the innovative minds at Pitch Ni...

Read more

Recent News

04 /04

Genomics for Health 2024

Don't miss Scailyte's CEO, Peter Nestorov, at the Genomics for Health 2024 event, bridging cutting-e...

Read more

The Year of the AI Nobel

2024 is being hailed as the "Year of the AI Nobel," marking a milestone as artificial intelligence (...

Read more

Recent News